https://www.statcounter.com/counter/counter.js
Web Analytics
Home » Posts tagged with » C-Bridge Capital
Samsung Bioepis, C-Bridge Capital collaborate to develop and commercialize biosimilars in China

Samsung Bioepis, C-Bridge Capital collaborate to develop and commercialize biosimilars in China

Samsung Bioepis, a South Korean biopharma company, has signed a licensing agreement with private equity firm C-Bridge Capital to develop and commercialize next-generation biosimilars in China. The agreement covers Samsung Bioepis’ various biosimilar candidates like SB11 and SB12, which reference LUCENTIS (ranibizumab) and SOLIRIS (eculizumab), respectively, and also SB3, a biosimilar candidate referencing HERCEPTIN 3 […]